Daxor Corporation announces that Daxor has received a $550K matching-fund extension from the U.S. Defense Health Agency to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminates the need for hematocrit testing from third-party devices to perform the BVA test.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor’s BVA-100 blood volume diagnostic expands to three new centers
- Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
- Daxor appoints Jefferies as Chief Medical Officer
- Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer